FURIN and COVID-19: A noteworthy feature of SARS-CoV-2 is a polybasic cleavage site at the terminal of the S1 and S2 subunits of the S glycoprotein, and this further allows effective cleavage by furin and other proteases and has a significant role in viral entry into host cells.29–31 Thus, the drive to develop anti-COVID-19 therapeutics should also involve evaluation of furin inhibitors.